Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBIT (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed EBIT for 15 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 82.24% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.8 million through Dec 2025, down 67.29% year-over-year, with the annual reading at $44.8 million for FY2025, 67.29% down from the prior year.
  • EBIT hit $4.5 million in Q4 2025 for Corcept Therapeutics, down from $10.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $46.6 million in Q3 2024 to a low of $3.4 million in Q1 2025.
  • Historically, EBIT has averaged $26.3 million across 5 years, with a median of $29.5 million in 2023.
  • Biggest five-year swings in EBIT: skyrocketed 98.61% in 2024 and later tumbled 88.42% in 2025.
  • Year by year, EBIT stood at $36.7 million in 2021, then crashed by 38.63% to $22.5 million in 2022, then skyrocketed by 40.76% to $31.7 million in 2023, then decreased by 20.23% to $25.3 million in 2024, then plummeted by 82.24% to $4.5 million in 2025.
  • Business Quant data shows EBIT for CORT at $4.5 million in Q4 2025, $10.2 million in Q3 2025, and $26.7 million in Q2 2025.